Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Astrazeneca Plc (AZN) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 65,502,840
  • Shares Outstanding, K 2,530,040
  • Annual Sales, $ 24,708 M
  • Annual Income, $ 2,825 M
  • 36-Month Beta 0.77
  • Price/Sales 2.65
  • Price/Book 4.39

Price Performance

See More
Period Period Low Period High Performance
1-Month
25.68 +0.55%
on 12/05/16
29.16 -11.45%
on 11/09/16
-1.84 (-6.65%)
since 11/04/16
3-Month
25.68 +0.55%
on 12/05/16
34.34 -24.81%
on 09/22/16
-7.49 (-22.49%)
since 09/02/16
52-Week
25.68 +0.55%
on 12/05/16
35.04 -26.31%
on 08/05/16
-8.10 (-23.88%)
since 12/04/15

Most Recent Stories

More News
TAGRISSO(R) (osimertinib) Demonstrates Superiority over Chemotherapy in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer

--TAGRISSO reduced risk of disease progression by 70% and improved progression-free survival (PFS) by almost six months

Pharma Stock Roundup: Nivalis Falls on Study Data, Priority Reviews for Merck's Keytruda

This week, companies like Merck (MRK) and Pfizer (PFE) provided updates on their pipelines.

Pharma Stock Roundup: Lilly Alzheimer's Drug Fails, J&J in Acquisition Talks with ALIOF

Lilly's (LLY) stock was hit by the company's announcement that its investigational Alzheimer's disease drug failed in a late-stage study.

Eli Lilly Hits 52-Week Low on Poor Data on Alzheimer's Drug

Eli Lilly's (LLY) shares touched a new 52-week low after its Alzheimer's disease candidate, solanezumab, failed to meet the primary endpoint in a phase III study.

Allergan Acquires Chase Pharma, Expands CNS Portfolio

Allergan (AGN) acquired Chase Pharmaceuticals Corporation for an upfront payment of $125 million.

AstraZeneca: FDA Lifts Hold on Head & Neck Cancer Trials

AstraZeneca plc (AZN) has resumed enrolment of new patients in head and neck cancer studies of durvalumab as the FDA has lifted a partial clinical hold.

Glaxo Files for COPD Drug; FluLaval Approved for Infants

GlaxoSmithKline plc (GSK) and Innoviva, Inc. (INVA) announced filing of a regulatory submission in the U.S. for a once-daily, closed triple combination therapy and received approval from the FDA for a...

Here's Why Immune Design Should Be in Your Portfolio Now

On Nov 18, 2016, we issued an updated report on Immune Design Corp. (IMDZ).

Pfizer (PFE) Ibrance Positive in Phase III Breast Cancer Study

Pfizer Inc. (PFE) announced that detailed results of phase III PALOMA-2 study evaluating the combination of its breast cancer drug Ibrance and Novartis AG's (NVS) Femara for the treatment of first-line...

Is Immunotherapy the Next Hot Industry for Biotech Stock Investors?

In this edition of the Dutram Report, Eric Dutram talks with Brad Loncar, the CEO of Loncar Investments who specializes in the world of immunotherapy. This approach is revolutionizing the cancer treatment...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Sell with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is in highly oversold territory. Beware of a trend reversal.

See More

Business Summary

AstraZeneca PLC is one of the top five pharmaceutical companies in the world based on sales and is a therapeutic leader in cardiovascular, gastrointestinal, oncology, anesthesia including pain management, central nervous system (CNS) and respiratory products. They are engaged in the research, development,...

See More

Support & Resistance

2nd Resistance Point 26.21
1st Resistance Point 26.01
Last Price 25.82
1st Support Level 25.65
2nd Support Level 25.49

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.